




PHARMACEUTICAL 2020

Rezolute Inc.
Rank 324 of 358





PHARMACEUTICAL 2020

Rezolute Inc.
Rank 324 of 358

The relative strengths and weaknesses of Rezolute Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Rezolute Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 18% points. The greatest weakness of Rezolute Inc. is the variable Net Income, reducing the Economic Capital Ratio by 163% points.

The company's Economic Capital Ratio, given in the ranking table, is -241%, being 277% points below the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	12,144
Cost of Goods Sold	0
Intangible Assets	29
Liabilities, Current	8,379
Liabilities, Non-Current	121
Other Assets	35
Other Compr. Net Income	0
Other Expenses	45
Other Liabilities	2,000
Other Net Income	-4,502
Other Revenues	0
Property and Equipment	44
Research and Development	19,079
Selling, General and Administrative Expense	6,820

Output Variable	Value in 1000 USD
Assets	12,252
Liabilities	10,500
Expenses	25,944
Revenues	0
Stockholders Equity	1,752
Net Income	-30,446
Comprehensive Net Income	-30,446
Economic Capital Ratio	-241%